
    
      The aim of this study is to compare efficacy of brigatinib and other 2nd-generation ALK
      tyrosin kinase inhibitor (TKI) in 1st and 2nd line treatment and to explore resistance
      patterns according to treatment and molecular properties of the tumors
    
  